

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
Group Art Unit : 1652
Applicants : Michael Mullican, et al.
Application No.: 10/060,662
Filed : January 30, 2002
For : ACYCLIC AND CYCLIC AMINE DERIVATIVES

Cambridge, Massachusetts
August 23, 2002

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application. This Statement is submitted:

- ☐ within three months of the application filing date;
- ☒ more than three months from the application filing date but before the mailing date of the first Office Action on the merits.

In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account

No. 06-1075. A duplicate copy of this letter is
transmitted herewith.

Respectfully submitted,



Nandakumar Govindaswamy
Limited Recognition
Attorney for Applicants
c/o VERTEX PHARMACEUTICALS
INCORPORATED
130 Waverly Street
Cambridge, Massachusetts 02139
Tel.: (617) 444-6467
Fax: (617) 444-6483



08-26-02
Packet No.: VPI/99-07 CON US

Certificate Of Mailing Under 37 C.F.R. § 1.10

Express Mailing No. EV 019 435 667 US

Date of Deposit: August 23 2002

1614
RECEIVED
AUG 30 2002
TECH CENTER 3600/2900

I hereby certify that the following documents:

1. Transmittal Letter for Information Disclosure Statement (in duplicate);
2. Information Disclosure Statement (in duplicate);
3. PTO-1449 Form (in duplicate);
4. Cited references A1-A7, B1 and C1-C2;
5. Copy of International Search Report; and
6. this return postcard receipt.


are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington D.C. 20231

Karen DiRocco

(type or printed name of person mailing document(s))

Karen DiRocco

(signature of person mailing document(s))



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
Group Art Unit : 1652
Applicants : Michael Mullican, et al.
Application No.: 10/060,662
Filed : January 30, 2002
For : ACYCLIC AND CYCLIC AMINE DERIVATIVES

Cambridge, Massachusetts
August 23, 2002

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 AND 1.97

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants,
through their agent, make of record the documents listed
below.

United States Patents

Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)
A1	6,004,993	12/21/1999	Steiner, et al.
A2	5,990,131	11/23/1999	Hamilton, et al.
A3	5,945,441	08/31/1999	Steiner, et al.
A4	5,840,736	11/24/1998	Zelle, et al.
A5	5,786,378	07/28/1998	Hamilton, et al.
A6	5,744,485	04/28/1998	Zelle, et al.
A7	5,721,256	02/24/1998	Hamilton, et al.

RECEIVED

AUG 30 2002

TECH CENTER 1600/2900

Foreign Patent Documents

Cite No.	Document Number	Name of Applicant(s)	Date of Publication
B1	WO 01/08685	Vertex Pharmaceuticals, Incorporated	08-Feb-2001

Non-Patent Documents

Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
C1	Database CA on STN. Chem. Abst. Vol. 132, (Columbus, OH, USA), abstract no. 237375, Li, et al., "Preparation of bridged heterocyclic derivatives for treatment of neurological and other disorders," WO 20000016603, 3 March 2000, see entire abstract.
C2	Database CA on STN Chem. Abstr. Vol. 132, 2000, (Columbus, OH, USA), abstract no. 175850, Ross, et al., "Compositions and uses for vision and memor disorders", WO 2000009108, 18 May 2000, see entire abstract.

Applicants have enclosed herewith copies of each document cited above. These references were cited in the December 15, 2000 International Search Report (copy enclosed) issued in the counterpart International Application No. PCT/US00/20491, filed July 27, 2000.

Applicants request that these documents: (1) be fully considered by the Examiner during examination of this application, and (2) be printed on any patent that may issue from this application.


A completed Form PTO-1449 listing all of the documents is enclosed herewith in duplicate. Applicants also request that a copy of the enclosed Form PTO-1449 duly initialed by the Examiner be forwarded to the undersigned with the next communication.

This Information Disclosure Statement is being submitted more than three months after the filing date but before the mailing of the first Office Action on the

merits. In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee.

The Director is, however, hereby authorized to charge to Deposit Account No. 50-0725 payment of any fees required in connection with the accompanying Information Disclosure Statement. A duplicate copy of this statement is transmitted herewith.

Respectfully submitted,



Nandakumar Govindaswamy
Limited Recognition
Attorney for Applicants
c/o VERTEX PHARMACEUTICALS
INCORPORATED
130 Waverly Street
Cambridge, Massachusetts 02139
Tel.: (617) 444-6467
Fax: (617) 444-6483

